Complement Inhibition in ANCA-Associated Vasculitis

Efficacy of immunosuppressive treatment of Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is complicated by its toxicity. With the replacement of cyclophosphamide with rituximab, serious adverse events seem to be associated especially with high-dose corticosteroids. Activati...

Descripción completa

Detalles Bibliográficos
Autores principales: Tesar, Vladimir, Hruskova, Zdenka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307875/
https://www.ncbi.nlm.nih.gov/pubmed/35880179
http://dx.doi.org/10.3389/fimmu.2022.888816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9307875/
https://www.ncbi.nlm.nih.gov/pubmed/35880179
http://dx.doi.org/10.3389/fimmu.2022.888816

Ejemplares similares